Literature DB >> 28640546

Treatment at high-volume facilities and academic centers is independently associated with improved survival in patients with locally advanced head and neck cancer.

John M David1,2, Allen S Ho2,3, Michael Luu4, Emi J Yoshida1,2, Sungjin Kim2,4, Alain C Mita2, Kevin S Scher2, Stephen L Shiao1,2, Mourad Tighiouart2,4, Zachary S Zumsteg1,2.   

Abstract

BACKGROUND: The treatment of head and neck cancers is complex and associated with significant morbidity, requiring multidisciplinary care and physician expertise. Thus, facility characteristics, such as clinical volume and academic status, may influence outcomes.
METHODS: The current study included 46,567 patients taken from the National Cancer Data Base who were diagnosed with locally advanced invasive squamous cell carcinomas of the oropharynx, larynx, and hypopharynx and were undergoing definitive radiotherapy. High-volume facilities (HVFs) were defined as the top 1% of centers by the number of patients treated from 2004 through 2012. Multivariable Cox regression and propensity score matching were performed to account for imbalances in covariates.
RESULTS: The median follow-up was 55.1 months. Treatment at a HVF (hazard ratio, 0.798; 95% confidence interval, 0.753-0.845 [P<.001]) and treatment at an academic facility (hazard ratio, 0.897; 95% confidence interval, 0.871-0.923 [P<.001]) were found to be independently associated with improved overall survival in multivariable analysis. In propensity score-matched cohorts, the 5-year overall survival rate was 61.6% versus 55.5% for patients treated at an HVF versus lower-volume facilities, respectively (P<.001). Similarly, the 5-year overall survival rate was 52.3% versus 49.7% for patients treated at academic versus nonacademic facilities (P<.001). Analysis of facility volume as a continuous variable demonstrated continual improvement in survival with an increased number of patients treated. The impact of facility volume and academic designation on survival was observed when using a variety of thresholds to define HVF, and across the vast majority of subgroups, including both oropharyngeal and nonoropharyngeal subsites.
CONCLUSIONS: Patients with locally advanced head and neck squamous cell carcinoma who are undergoing curative radiotherapy at HVFs and academic centers appear to have improved survival. Cancer 2017;123:3933-42.
© 2017 American Cancer Society. © 2017 American Cancer Society.

Entities:  

Keywords:  National Cancer Data Base; academic center; chemoradiation; facility volume; head and neck cancer; radiation

Mesh:

Year:  2017        PMID: 28640546     DOI: 10.1002/cncr.30843

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  17 in total

1.  Nomogram to Predict the Benefit of Intensive Treatment for Locoregionally Advanced Head and Neck Cancer.

Authors:  Loren K Mell; Hanjie Shen; Phuc Felix Nguyen-Tân; David I Rosenthal; Kaveh Zakeri; Lucas K Vitzthum; Steven J Frank; Peter B Schiff; Andy M Trotti; James A Bonner; Christopher U Jones; Sue S Yom; Wade L Thorstad; Stuart J Wong; George Shenouda; John A Ridge; Qiang E Zhang; Quynh-Thu Le
Journal:  Clin Cancer Res       Date:  2019-08-16       Impact factor: 12.531

2.  Radiation therapy treatment facility and overall survival in the adjuvant setting for locally advanced head and neck squamous cell carcinoma.

Authors:  Nicholas C J Lee; Jacqueline R Kelly; Yi An; Henry S Park; Benjamin L Judson; Barbara A Burtness; Zain A Husain
Journal:  Cancer       Date:  2019-02-12       Impact factor: 6.860

3.  The impact of the Patient Protection and Affordable Care Act on insurance coverage and cancer-directed treatment in HIV-infected patients with cancer in the United States.

Authors:  Kelsey L Corrigan; Leticia Nogueira; K Robin Yabroff; Chun Chieh Lin; Xuesong Han; Junzo P Chino; Anna E Coghill; Meredith Shiels; Ahmedin Jemal; Gita Suneja
Journal:  Cancer       Date:  2019-11-11       Impact factor: 6.860

4.  Head and neck squamous cell cancers in the United States are rare and the risk now is higher among white individuals compared with black individuals.

Authors:  Carole Fakhry; Martin Krapcho; David W Eisele; Gypsyamber D'Souza
Journal:  Cancer       Date:  2018-03-13       Impact factor: 6.860

5.  Development of a novel salivary gland cancer lymph node staging system.

Authors:  Katri Aro; Allen S Ho; Michael Luu; Sungjin Kim; Mourad Tighiouart; Jon Mallen-St Clair; Emi J Yoshida; Stephen L Shiao; Ilmo Leivo; Zachary S Zumsteg
Journal:  Cancer       Date:  2018-05-09       Impact factor: 6.860

6.  Racial and Ethnic Disparities in Travel for Head and Neck Cancer Treatment and the Impact of Travel Distance on Survival.

Authors:  Evan M Graboyes; Mark A Ellis; Hong Li; John M Kaczmar; Anand K Sharma; Eric J Lentsch; Terry A Day; Chanita Hughes Halbert
Journal:  Cancer       Date:  2018-06-22       Impact factor: 6.860

7.  Characteristics and overall survival in pediatric versus adult pituitary adenoma: a National Cancer Database analysis.

Authors:  Benjamin F Bitner; Brandon M Lehrich; Arash Abiri; Tyler M Yasaka; Frank P K Hsu; Edward C Kuan
Journal:  Pituitary       Date:  2021-04-30       Impact factor: 4.107

8.  The influence of facility volume on patient treatments and survival outcomes in nasopharyngeal carcinoma.

Authors:  Khodayar Goshtasbi; Arash Abiri; Brandon M Lehrich; Yarah M Haidar; Tjoson Tjoa; Edward C Kuan
Journal:  Head Neck       Date:  2021-05-17       Impact factor: 3.821

9.  Therapy Effects of Advanced Hypopharyngeal and Laryngeal Squamous Cell Carcinoma: Evaluated using Dual-Energy CT Quantitative Parameters.

Authors:  Liang Yang; Dehong Luo; Junlin Yi; Lin Li; Yanfeng Zhao; Meng Lin; Wei Guo; Lei Hu; Chunwu Zhou
Journal:  Sci Rep       Date:  2018-06-13       Impact factor: 4.379

10.  Is There a Difference in Staging and Treatment of Head and Neck Squamous Cell Tumors Between Tertiary Care and Community-Based Institutions?

Authors:  Sarah R Akkina; Roderick Y Kim; Chaz L Stucken; Melissa A Pynnonen; Carol R Bradford
Journal:  Laryngoscope Investig Otolaryngol       Date:  2018-08-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.